microRNAs: Potential targets for the treatment of cardiovascular disease

Current Vascular Pharmacology

Volumn 13, Issue 3, 2015, Pages 366-367

  Athyros, Vasilios G ^a   Katsiki, Niki ^a   Karagiannis, Asterios ^a  

^a ARISTOTLE UNIVERSITY MEDICAL SCHOOL   (Greece)

Author keywords

Antisense oligonucleotides; Cardiovascular disease; Diabetes; Metabolic syndrome; MicroRNA; MicroRNA mimics; Obesity; Silencing

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; EPHRIN A3; MICRORNA; MICRORNA 106; MICRORNA 125A; MICRORNA 126; MICRORNA 136; MICRORNA 143; MICRORNA 145; MICRORNA 15A; MICRORNA 21; MICRORNA 210; MICRORNA 223; MICRORNA 27A; MICRORNA 27B; MICRORNA 28 3P; MICRORNA 29; MICRORNA 320; MICRORNA 335; MICRORNA 378; MICRORNA 758; MICRORNA 9; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHATIDYLINOSITOL 3, 4, 5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN BCL 2; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN; UNTRANSLATED RNA;

ABDOMINAL AORTA ANEURYSM; ANGIOGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CELL DIFFERENTIATION; CELL PROLIFERATION; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DOWN REGULATION; DRUG TARGETING; EDITORIAL; ENDOTHELIUM CELL; GENE; GENE EXPRESSION; GENE OVEREXPRESSION; GENE SILENCING; HEART MUSCLE FIBROSIS; HUMAN; LIPID METABOLISM; METABOLIC SYNDROME X; NONHUMAN; OBESITY; PATHOGENESIS; PPP2R2A GENE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SAFETY; VASCULAR SMOOTH MUSCLE CELL; VASCULITIS; ANIMAL; CARDIOVASCULAR DISEASES; DRUG EFFECTS; GENE THERAPY; GENETICS;

ANIMALS; CARDIOVASCULAR DISEASES; GENE SILENCING; GENETIC THERAPY; HUMANS; MICRORNAS; RNA, UNTRANSLATED;

EID: 84937128430     PISSN: 15701611     EISSN: 18756212     Source Type: Journal    
DOI: 10.2174/157016111303150707103801     Document Type: Editorial

References (23)

1. [1] Montgomery RL, van Rooij E. Therapeutic advances in MicroRNA targeting. J Cardiovasc Pharmacol 2011; 57: 1-7.
2. [2] De Rosa S, Curcio A, Indolfi C. Emerging Role of MicroRNAs in Cardiovascular Diseases. Circ J 2014; 78: 567-75.
3. [3] Kang K, Zhang C, Li X, Xie B. MicroRNA-136 promotes vascular muscle cell proliferation through ERK1/2 pathway by targeting PPP2R2A in atherosclerosis. Curr Vasc Pharmacol 2015; 13(3): 405-12.
4. [4] Marx SO, Totary-Jain H, Marks AR. Vascular smooth muscle cell proliferation in restenosis. Circ Cardiovasc Interv 2011; 4: 104-11.
5. [5] Shen S, Yue H, Li Y, Qin J, Li K, Liu Y, Wang J. Upregulation of miR-136 in human non-small cell lung cancer cells promotes Erk1/2 activation by targetingPPP2R2A. Tumour Biol 2014; 35(1): 631-40.
6. [6] Pagès G, Guérin S, Grall D, et al. Defective thymocyte maturation in p44 MAP kinase (Erk 1) knockout mice. Science 1999; 286: 1374-7.
7. [7] Harris TA, Yamakuchi M, Ferlito M, Mendell JT, Lowenstein CJ. MicroRNA-126 regulates endothelial expression of vascular cell adhesion molecule 1. Proc Natl Acad Sci USA 2008; 105: 1516-21.
8. [8] Fish JE, Santoro MM, Morton SU, et al. miR-126 regulates angiogenic signaling and vascular integrity. Dev Cell 2008; 15: 272-84.
9. [9] Zampetaki A, Kiechl S, Drozdov I, et al. Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes. Circ Res 2010; 6: 810-7.
10. [10] Suarez Y, Wang C, Manes TD, Pober JS. Cutting edge: TNF-induced microRNAs regulate TNF induced expression of E-selectin and intercellular adhesion molecule-1 on human endothelial cells: feedback control of inflammation. J Immunol 2010; 184: 21-5.
11. [11] Fasanaro P, D’Alessandra Y, Di Stefano V, et al. MicroRNA-210 modulates endothelial cell response to hypoxia and inhibits the receptor tyrosine kinase ligand Ephrin-A3. J Biol Chem 2008; 283: 15878-83.
12. [12] Kang H, Davis-Dusenbery BN, Nguyen PH, et al. Bone morphogenetic protein 4 promotes vascular smooth muscle contractility by activating microRNA- 21 (miR-21), which down-regulates expression of family of dedicator of cytokinesis (DOCK) proteins. J Biol Chem 2012; 287: 3976-86.
13. [13] Maegdefessel L, Azuma J, Toh R, et al. MicroRNA-21 blocks abdominal aortic aneurysm development and nicotine-augmented expansion. Sci Transl Med 2012; 4: 122ra22.
14. [14] Fernández-Hernando C, Baldán A. MicroRNAs and Cardiovascular Disease. Curr Genet Med Rep 2013; 1: 30-38.
15. [15] Guay C, Roggli E, Nesca V, Jacovetti C, Regazzi R. Diabetes mellitus, a microRNA-related disease? Transl Res 2011; 157: 253-64.
16. [16] Shantikumar S, Caporali A, Emanueli C. Role of microRNAs in diabetes and its cardiovascular complications. Cardiovasc Res 2012; 93: 583-93.
17. [17] Heneghan HMI, Miller N, Kerin MJ. Role of microRNAs in obesity and the metabolic syndrome. Obes Rev 2010; 11: 354-61.
18. [18] Rotllan N, Ramírez CM, Aryal B, Esau CC, Fernández-Hernando C. Therapeutic silencing of microRNA-33 inhibits the progression of atherosclerosis in Ldlr-/- mice--brief report. Arterioscler Thromb Vasc Biol 2013; 33: 1973-7.
19. [19] Mikhailidis DP, Athyros VG. Dyslipidaemia in 2013: New statin guidelines and promising novel therapeutics. Nat Rev Cardiol 2014; 11: 72-4.
20. [20] Rayner KJ, Suarez Y, Davalos A, et al. MiR-33 contributes to the regulation of cholesterol homeostasis. Science 2010; 328: 1570-3.
21. [21] Allen RM, Marquart TJ, Albert CJ, et al. miR-33 controls the expression of biliary transporters, and mediates statin- and diet-induced hepatotoxicity. EMBO Mol Med 2012; 4: 882-95.
22. [22] Ramírez CM, Goedeke L, Fernández-Hernando C. “Micromanaging” metabolic syndrome. Cell Cycle 2011; 10: 3249-52.
23. [23] Wei YI, Nazari-Jahantigh M, Neth P, Weber C, Schober A. MicroRNA-126, -145, and -155: a therapeutic triad in atherosclerosis? Arterioscler Thromb Vasc Biol 2013; 33: 449-54.